On 30 August, at this year’s European Society of Cardiology (ESC) conference, during a late-breaking science session on the topic of “Pharmacotherapy,” Thomas Hauser presented results from the randomised, double-blind, placebo-controlled study, which investigated the safety and tolerability of XXB750.
According to the results, Novartis’s XXB750 was safe and well tolerated in patients with chronic stable heart failure (HF) with reduced or mildly reduced ejection fraction (EF). XXB750 acts as natriuretic peptide receptor A agonist and is currently in a Phase II trial. The drug is administered through subcutaneous route (SC). Key opinion leaders (KOLs) interviewed by GlobalData have emphasised that patients would favour a subcutaneous administration over adding more pills to their regimen.
Go deeper with GlobalData
Hauser highlighted that a single 120 mg SC dose and multiple SC doses of 120mg, 120 mg, and 240 mg of XXB750 every 4 weeks was generally safe and well tolerated in patients with chronic stable HF with reduced or mildly reduced EF on background angiotensin-converting-enzyme inhibitors/angiotensin receptor blockers or sacubitril/valsartan. In addition, pharmacokinetic exposure possibly supports monthly dosing. A mild, transient increase in heart rate was observed in the XXB750 group but most adverse events were mild.
HF is a critical clinical condition where certain structural and functional abnormalities in the heart impair its ability to meet systemic circulation. The various causes that contribute to these abnormalities are hypertension, arrythmia, valvular heart disease, and risk factors including high cholesterol, infection, and genetic factors.
There is a strong opportunity in the HF space for new agents that could further reduce the incidence of HF-associated hospitalisations and mortality. According to GlobalData’s Pharma Intelligence Center Drug Database, there are two atrial natriuretic peptide receptor 1 agonists marketed for acute HF: Daiichi Sankyo’s Hanp (carperitide) and China Medical System Holdings’ Xinhuosu (nesiritide).
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Related Company Profiles
Novartis AG
Daiichi Sankyo Co Ltd
China Medical System Holdings Ltd